Sign In

Ram Aiyar

Professional based in Greater Boston

Ram Aiyar, Ph.D., MBA, is the Chief Executive Officer and President of Korro Bio, Inc., a biotechnology company specializing in RNA editing therapies. He has nearly two decades of experience in the biotech and pharmaceutical industries, where he has worked across various stages of development, from clinical trials to commercialization.

Career Overview

Before joining Korro Bio in November 2020, Aiyar co-founded Corvidia Therapeutics, where he served as Chief Financial Officer and Chief Business Officer. He played a pivotal role in the company's growth and led its acquisition by Novo Nordisk for $2.1 billion. His previous roles include positions at BioHealth Innovation as an entrepreneur-in-residence, and leadership roles at FlowMetric Inc., Sofinnova Partners, and J.P. Morgan Chase.

Aiyar began his scientific career in research at Janssen Pharmaceuticals' immunology group and has a robust background in corporate development, finance, and strategy.

Education

Ram Aiyar holds a Master of Science (M.S.) and a Ph.D. in Electrical and Computer Engineering from Drexel University, along with an MBA in Finance and Business Strategy from INSEAD (France/Singapore) .123

Contributions to Korro Bio

At Korro Bio, Aiyar is focused on advancing the company's proprietary RNA editing platform, OPERA (Oligonucleotide Promoted Editing of RNA), which aims to treat diseases by repairing mutations at the RNA level. His leadership is expected to drive innovation in genetic medicine, particularly targeting conditions that have been difficult to treat with traditional approaches .24

Highlights

Dec 7 · linkedin

It's a big day for Korro as we nominated our first development candidate (KRRO-110), and the potential best-in-class therapy it brings for patients with Alpha 1 Anti-trypsin Deficiency (AATD).

We believe we can bring AATD patients to as close to "normal" (>50% editing of RNA with >70% of normal A1AT in preclinical mouse models).

We look forward to working with our clinical advisors, including Dr. Jeff Teckman who has seen this program from its inception.

#RNAEditing $KRRO #KorroBio #AATD #KorroKrew

Feb 21 · linkedin

Completed an unbelievable journey to the top of Africa’s tallest mountain - Mt. Kilimanjaro @19.3k ft. Along the journey, raised >$1M for cancer research at the Fred Hutch under the leadership of Luke Timmerman, met 20 other amazing biotech executives from across the US and learned about their journeys, and an amazing crew of Tanzanians without whose support this would not have been possible.

Thank you to my major sponsors Goodwin, Stifel Financial Corp. and Cresa for supporting this endeavor. I would also like to thank and appreciate the countless individuals who have lent their support including the Krew at Korro Bio, Inc.

This was a first for me on multiple levels and much like developing a novel class of drugs, requires both a mental grit and physical strength to do hard things. Watch out for the folks in this group to accomplish big things!

#AlpineAscents #FredHutch #AlwaysNeedAKrew #AfricaAdventures

Related Questions

What are Ram Aiyar's key achievements at Corvidia Therapeutics?
How did Ram Aiyar's role at Janssen Pharmaceuticals influence his career?
What is the significance of Korro Bio's RNA editing platform?
What are the main therapeutic areas Korro Bio is focusing on?
How did Ram Aiyar's experience at BioHealth Innovation shape his leadership style?
Ram Aiyar
Ram Aiyar, photo 1
Ram Aiyar, photo 2
Add to my network

Experience

Korro Bio, Inc.

Education

INSEAD

Location

Greater Boston